Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation

作     者：Wattana Leowattana Tawithep Leowattana Pathomthep Leowattana 

作者机构：Department of Clinical Tropical MedicineFaculty of Tropical MedicineMahidol UniversityBangkok 10400Thailand Department of MedicineFaculty of MedicineSrinakharinwirot UniversityBangkok 10110Thailand 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2022年第10卷第27期

页      面：9588-9601页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Atrial fibrillation Human-induced pluripotent stem cell-derived atrial cardiomyocytes Disease modeling Maturation Pharmacologic response Personalized medicine 

摘      要：Patient-specific human-induced pluripotent stem cell-derived atrial cardiomyocytes(hiPSC-aCMs) may be produced,genome-edited,and differentiated into multiple cell types for regenerative medicine,disease modeling,drug testing,toxicity screening,and three-dimensional tissue *** is presently no complete model of atrial fibrillation(AF) available for studying human pharmacological responses and evaluating the toxicity of potential medication *** has been demonstrated that hiPSC-aCMs can replicate the electrophysiological disease phenotype and genotype of *** hiPSC-aCMs,however,are immature and do not reflect the maturity of a CMs in the native *** laboratories utilize a variety of methodologies and procedures to improve and promote a CM maturation,including electrical stimulation,culture duration,biophysical signals,and changes in metabolic *** review covers the current methods being explored for use in the maturation of patient-specific hiPSC-aCMs and their application towards a personalized approach to the pharmacologic therapy of AF.